NeuroSense Therapeutics Warrant
NRSNW
3 hedge funds and large institutions have $16.1K invested in NeuroSense Therapeutics Warrant in 2025 Q1 according to their latest regulatory filings, with funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
0.14% less ownership
Funds ownership: 0.54% → 0.4% (-0.14%)
25% less funds holding
Funds holding: 4 → 3 (-1)
63% less capital invested
Capital invested by funds: $43.9K → $16.1K (-$27.7K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$718 |
| 2 |
CS
Clear Street
New York
|
+$26 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$7.04K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$2.08K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
1
Clear Street
New York
| $13.5K | +$26 | +100 | +0.2% |
|
|
WAM
2
Warberg Asset Management
Winnetka,
Illinois
| $2.05K | -$2.08K | -7,936 | -44% |
|
|
3
UBS Group
Zurich,
Switzerland
| $582 | +$718 | +2,747 | +2,922% |
|
|
4
Citadel Advisors
Miami,
Florida
| – | -$7.04K | -22,711 | Closed |
|
NRSNW Hedge Fund Activity: Q1 2025 in Review
3 of the 7,459 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q1 2025, worth a combined $16.1K — down 63% from $43.9K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NRSNW and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $718. The largest seller was Citadel Advisors, exiting entirely with an estimated $7.04K sold.
- 3 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q1 2025, down from 4 in Q4 2024.
- Funds reported $16.1K of NeuroSense Therapeutics Warrant stock for Q1 2025, down 63% quarter-over-quarter.
- 0 funds opened new NeuroSense Therapeutics Warrant positions in Q1 2025 and 1 closed out, a net change of -1 holder.
- The largest NeuroSense Therapeutics Warrant buyer in Q1 2025 was UBS Group, an estimated $718 added.
- The largest NeuroSense Therapeutics Warrant seller in Q1 2025 was Citadel Advisors, an estimated $7.04K sold.
Based on aggregated 13F filings for Q1 2025.